(Q38043814)

27 August 2017

title

Using metabolomics to assess myocardial metabolism and energetics in heart failure (English)

1 reference

27 August 2017

0 references

1 reference

Aslan T Turer

1

1 reference

27 August 2017

publication date

7 September 2012

1 reference

Journal of Molecular and Cellular Cardiology

27 August 2017

published in

1 reference

27 August 2017

volume

55

1 reference

27 August 2017

page(s)

12-18

1 reference

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Trends in Heart Failure Incidence and Survival in a Community-Based Population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Hospitalizations after heart failure diagnosis a community perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Long-Term Trends in the Incidence of and Survival with Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Human myocardial ATP content and in vivo contractile function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Bioenergetics: Dissecting the role of creatine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

A simple analysis of the "phosphocreatine shuttle"

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Creatine kinase system in failing and nonfailing human myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Ventricular adenine nucleotide translocator mRNA is upregulated in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Transgenesis and cardiac energetics: new insights into cardiac metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Energetic crosstalk between organelles: architectural integration of energy production and utilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Glycolysis supports calcium uptake by the sarcoplasmic reticulum in skinned ventricular fibres of mice deficient in mitochondrial and cytosolic creatine kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Mechanisms of creatine depletion in chronically failing rat heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Creatine transporter activity and content in the rat heart supplemented by and depleted of creatine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Regulation of the creatine transporter by AMP-activated protein kinase in kidney epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Supranormal myocardial creatine and phosphocreatine concentrations lead to cardiac hypertrophy and heart failure: insights from creatine transporter-overexpressing transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Impaired cardiac energetics in mice lacking muscle-specific isoenzymes of creatine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Cardiac metabolic compensation to hypertension requires lipoprotein lipase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Lipotoxic heart disease in obese rats: implications for human obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

A murine model of isolated cardiac steatosis leads to cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Ceramide is a cardiotoxin in lipotoxic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Diabetic cardiomyopathy revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Recognition and management of fatty acid oxidation defects: a series of 107 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Disorders of carnitine transport and the carnitine cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Fatty acid oxidation enzyme gene expression is downregulated in the failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolic gene expression in fetal and failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolic remodelling of the failing heart: beneficial or detrimental?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Return to the fetal gene program protects the stressed heart: a strong hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Energetics and metabolism in the failing heart: important but poorly understood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Total-body and myocardial substrate oxidation in congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Myocardial perfusion reserve and oxidative metabolism contribute to exercise capacity in patients with dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Substrate utilization by the failing human heart by direct quantification using arterio-venous blood sampling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolomics as a tool for cardiac research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

HMDB: a knowledgebase for the human metabolome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolomics and cardiovascular biomarker discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolomics in angiotensin II-induced cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

¹H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Myocardial substrate metabolism in the normal and failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Combined metabolomic and proteomic analysis of human atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolite profiles and the risk of developing diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

A novel mouse model of lipotoxic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Palmitate-induced apoptosis can occur through a ceramide-independent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolomic identification of novel biomarkers of myocardial ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolic signatures of exercise in human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Assessment of Metabolic Phenotypes in Patients with Non-ischemic Dilated Cardiomyopathy Undergoing Cardiac Resynchronization Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

On getting there from here

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Delineation of substrate selection and anaplerosis in tricarboxylic acid cycle of the heart by 13C NMR spectroscopy and mass spectrometry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Effects of amino acids on substrate selection, anaplerosis, and left ventricular function in the ischemic reperfused rat heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Effects of glutamate and aspartate on myocardial substrate oxidation during potassium arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Contribution of various substrates to total citric acid cycle flux and anaplerosis as determined by 13C isotopomer analysis and O2 consumption in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Flux through hepatic pyruvate carboxylase and phosphoenolpyruvate carboxykinase detected by hyperpolarized 13C magnetic resonance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Inhibition of carbohydrate oxidation during the first minute of reperfusion after brief ischemia: NMR detection of hyperpolarized 13CO2 and H13CO3-.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

The cycling of acetyl-coenzyme A through acetylcarnitine buffers cardiac substrate supply: a hyperpolarized 13C magnetic resonance study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

Could 13C MRI assist clinical decision-making for patients with heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.08.025

10.1016/J.YJMCC.2012.08.025

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference